Featured Articles

No Image

OneMedRadio: ADVENTRX Hosts First Annual Sickle Cell Disease Therapeutics Conference

September 14, 2012 OneMedPlace Team 0

September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.

No Image

BREAKING: Pluristem Announces Pricing of Public Offering

September 13, 2012 OneMedPlace Team 0

Pluristem Therapeutics Inc. announced that it has priced a firm commitment underwritten public offering of 8,000,000 units, with each unit consisting of one share of the company’s common stock and one warrant to purchase 0.35 of a share of the company’s common stock, at a purchase price of $4.00 per unit for an aggregate gross offering amount of $32 million. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions.

No Image

Obesity Drug Market: Can Dramatic Returns Outweigh the Risk?

September 12, 2012 OneMedPlace Team 0

Arena and Vivus’ approval of their obesity drugs — the first such approved in 13 years — have sent shockwaves throughout the industry. With Orexigen’s drug on the way, these have the potential to dramatically alter an entire sub-sector once left for dead. Still, despite positive data and FDA support, these drugs did not reach approval phase without several speed bumps along the way. And more questions are yet to come.

No Image

BREAKING: Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

September 12, 2012 OneMedPlace Team 0

Opexa Therapeutics, Inc. today announced the initiation of a Phase IIb clinical trial of Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), in patients with Secondary Progressive Multiple Sclerosis (SPMS). The therapy is specifically tailored to each patient’s individual disease profile and has demonstrated superior safety and encouraging indications of efficacy in previous clinical studies in MS that included the treatment of SPMS patients.

No Image

Ann Romney, Michelle Obama Rally For Their Ticket – And The MS Population

September 10, 2012 OneMedPlace Team 2

With the 2012 Presidential election upon us, healthcare – both as a social service and essential sector of our economy – is once again a main pillar in the heated political debate. Ann Romney and Michelle Obama, both with a direct connection to Multiple Sclerosis, have opened up to campaign supporters in recent months about the effects of this debilitating disease.

No Image

Bulls, Bears: 3 Promising Stocks in Metastatic Cancer

September 5, 2012 OneMedPlace Team 1

In this special series, we explore the state of select public companies operating in a particularly intriguing area of life sciences. This week, we look at metastatic cancer, an area of significant unmet need. These companies, including OncoSec Medical, are having success with their innovative approaches to treating metastatic cancer, and are seeing results in their performance int he public markets.

No Image

2012 BDO IPO Halftime Report: Current Market Trends

August 28, 2012 MMargolis 0

As Ryan Starkes, Partner and a Practice Leader within BDO’s Technology and Life Sciences Industry Group informs us, BDO is interested in emerging growth life science companies particularly those planning on exploring international development. All companies looking to utilize the capital markets in the U.S., including those in the life sciences industry, have always had to navigate particularly perplexing regulatory requirements.